CHAPTER 12: Drug–Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspective
-
Published:20 Nov 2015
-
Special Collection: 2015 ebook collectionSeries: Drug Discovery Series
C. Tang, J. Hochman, and T. Prueksaritanont, in New Horizons in Predictive Drug Metabolism and Pharmacokinetics, ed. A. G. E. Wilson, The Royal Society of Chemistry, 2015, pp. 263-282.
Download citation file:
In this review, a number of theoretical bases and regulatory framework are presented for drug–drug interactions (DDIs), with emphasis on those related to absorption and distribution. Also presented is an industry perspective on how to approach these issues in support of drug development. Overall, holistic integration and understanding of the pharmaceutical (e.g., pH-dependent solubility) and pharmacological (e.g., gastrointestinal physiology and therapeutic margin) profiles, as well as pharmacokinetics and underlying absorption and disposition determinants (e.g., clearance, volume of distribution, permeability and protein binding) of drug candidates in various clinical setting should be considered as this can be valuable in ensuring the safe and effective use of new drugs.